Closing the Gap in Pediatric Pneumococcal Protection
A position statement calling for equitable pneumococcal vaccine protection for children in Nova Scotia, New Brunswick, Prince Edward Island and Newfoundland and Labrador.
Every child deserves access to strong, evidence-based protection against serious pneumococcal disease, regardless of where they live.
A Child's Protection Shouldn't Depend on Their Postal Code.
Pneumococcal disease can cause meningitis, bloodstream infections and pneumonia. Young children are among those at greatest risk.
Offers protection targeting 20 pneumococcal serotypes, including five additional serotypes not covered by PCV15.
Currently offered in Nova Scotia, New Brunswick, Prince Edward Island and Newfoundland and Labrador. It provides protection targeting the 15 serotypes it covers.
The National Advisory Committee on Immunization considers both PCV15 and PCV20 appropriate for healthy children and expects PCV20 to have a larger impact on invasive pneumococcal disease.
The Atlantic provinces have established strong infant immunization programs, offering free pneumococcal vaccination to every baby and adopting newer vaccines following national guidance. Expanding routine access to PCV20 would build on these foundations.
Why It Matters Now
Changing disease patterns, antibiotic resistance and differences in vaccine coverage highlight the importance of continued prevention efforts.
Pneumococcal Disease Is Back
Pneumococcal disease has returned to pre-pandemic levels. Rates in children aged one to four reached a ten-year high in 2022.
Antibiotic Resistance Is Rising
Across all ages, multidrug-resistant invasive pneumococcal disease rose from 8.4% to 13.2% of tested isolates between 2019 and 2023.
Some Children Face Greater Risks
Certain conditions increase a child's risk of severe infection. These conditions are not always diagnosed when vaccination begins, making broader coverage from the first dose especially important.
Prevention Benefits Communities
Preventing severe disease can reduce emergency visits, hospital stays, antibiotic use and time away from work for parents and caregivers.
Our Questions for Atlantic Governments
We respectfully ask the Ministers of Health and Chief Medical Officers of Health of the four Atlantic provinces to consider the following:
Broader Access
Atlantic provincial governments should broaden access to PCV20 to every infant in the routine immunization program.
Regional Collaboration
Atlantic provincial governments should act together as a region, sharing implementation tools, public messaging, and clinician training.
Protection for Higher-Risk Children
Atlantic provincial governments should ensure children at higher risk receive PCV20 according to NACI’s recommended four-dose schedule.
Measuring Progress
Atlantic provincial governments should measure, and report results each year, starting with vaccine coverage and serotype-specific invasive pneumococcal disease in young children.
A Message for Parents
Keep Your Child's Vaccines on Schedule.
The vaccine Atlantic infants receive today protects well against the 15 serotypes it covers.
If you have questions about your child's vaccinations, speak with your health-care provider or local public health office.
Share the Statement
Help us make sure every family in Atlantic Canada knows about this difference in vaccine coverage.
Read the full position statement and share it with your community.
Share This Page
Pneumonia Awareness Consortium
The Pneumonia Awareness Consortium is a collaboration of health advocates, including non-governmental organizations, dedicated to spreading evidence-based knowledge and preventing respiratory diseases through education, outreach and community support.
Learn More About the Consortium ↗Society for Intelligence Management
The Society for Intelligence Management (SIM) is an independent association promoting evidence-based knowledge translation, education, communication and informed decision-making.
SIM provides secretariat support to the Pneumonia Awareness Consortium.
Learn More About SIM ↗This statement was made possible through financial support from Pfizer Canada ULC.